CSI Market
Sign In | Register

Assembly Biosciences Inc (ASMB) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ASMB Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Assembly Biosciences Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-12.94
Depreciation & amortization0.05
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation3.53
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Stock Based Compensation Expense For Services-
Debt Conversion Converted Instrument Amount-
Investment Income Net Amortization Of Discount And Premium-
Accretion And Amortization Of Investments In Marketable Securities-
Noncash Rent Expense0.20
Increase Decrease In Contract With Customer Liability-7.83
Goodwill And Intangible Asset Impairment-
Increase Decrease In Accrued Research And Development Expenses-0.85
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.15
Increase (Decrease) in Accounts Payable-0.11
Increase (Decrease) in Other Accrued Liabilities-4.41
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.33
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-24.88
Discontinued operations0.00
Net Cash flow from Operating Activities-37.59
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities111.36
Payments to Acquire Available-for-sale Securities, Debt-208.80
Real Estate Investments0.00
Redemption Of Marketable Securities-
Payments For Security Deposits Collected-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-97.46
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.38
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net108.51
Proceeds From Exercise Of Stock Options And Warrants-
Accrued Offering Cost Related To Issuance Of Common Stock-
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan-
Proceeds From Issuance Of Common Stocks Under Employee Stock Purchase Plan-
Proceeds From Issuance Of Common Stock To Related Party-
Proceeds From Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Warrants In Private Placements To Related Party Net Of Issuance Costs-
Proceeds From The Issuance Of Common Stock And Warrants In A Registered Direct Offering Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations58.45
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities108.88
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-37.60
Total Cash Flow-26.16
4 historic quarters locked

Sign in to unlock the full Assembly Biosciences Inc cash flow history.

Sign In Create Free Account

About Assembly Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-349236

Figures are derived from filed reports and may be restated. Historical data is subject to revision.